Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06181149
Other study ID # R01DC020162
Secondary ID 1R01DC020162-01A
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2024
Est. completion date December 30, 2027

Study information

Verified date January 2024
Source Arizona State University
Contact Ayoub Daliri, PhD
Phone 4807278397
Email ayoub.daliri@asu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Stuttering negatively impacts communication and reduces the overall quality of life and well-being of individuals who stutter. This study will provide a strong foundation for developing neural and behavioral interventions for stuttering. Participants will be asked to name pictures, read words/sentences silently or aloud, and listen to speech and nonspeech sounds while their speech, muscle, and brain signals are collected. Some participants may also receive brain stimulation while reading and speaking.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 30, 2027
Est. primary completion date December 30, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Years and older
Eligibility Inclusion Criteria: - being a monolingual, native speaker of American English - absence of developmental, psychological, neurological, or communication disorders (other than developmental stuttering) as confirmed by a certified research SLP - normal (age-appropriate) binaural pure-tone hearing threshold (0.5-4k Hz; =25 dB HL for younger than 70 years, and =35 dB HL for older than 70 years) - not taking any medications that affect the central nervous system - absence of safety contra-indication for tDCS, TMS and MRI (for adults) - scoring at the 20th percentile or higher on standardized speech-language tests (for children) Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Delaying speech initiation
This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use transcranial magnetic stimulation to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.
Auditory errors and pre-speech auditory modulation
This intervention will examine the contributions of auditory errors to pre-speech auditory modulation. Participants will receive auditory perturbations while speaking, and we will collect their brain activities throughout the study.
Contributions of the speech premotor cortex to pre-speech auditory modulation
This intervention will examine the effects of stimulation of the left ventral premotor cortex on pre-speech auditory modulation. Participants will receive electrical stimulation while speaking.
Delaying auditory feedback
This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use delayed auditory feedback to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.

Locations

Country Name City State
United States Univeristy of Washington Seattle Washington
United States Arizona State University Tempe Arizona

Sponsors (3)

Lead Sponsor Collaborator
Arizona State University National Institute on Deafness and Other Communication Disorders (NIDCD), University of Washington

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in brain activity before and during speaking Participants will hear speech sounds in each trial before speaking or reading words. Participants' brain activity will be recorded while completing the speaking or reading tasks. The investigators will measure how the participant's brain activity in response to the played sounds changes during speaking and reading tasks. For this purpose, the investigators will measure the amplitude of the brain activity (in microvolts; µV) measured using a commercial electroencephalography system. The amplitude (µV) of the brain signals will be examined both before speaking and during speaking at two time points. within each session of the study that may last up to 2 hours
Primary change in speech when participants experience auditory errors In each trial, participants will experience an auditory error while they produce speech (e.g., they may say "head" but hear "had"). The investigators will measure how the participants' speech changes due to auditory errors that they experience in the current trial. For this p[purpose, the investigators will use commercial microphones to record speech signals and then examine the amplitude of the speech in specific frequency ranges (measured in Hertz; Hz). The frequencies (Hz) of speech in trials with auditory errors will be compared with those without auditory errors. within each session of the study that may last up to 2 hours
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1